Navigation Links
VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Date:3/12/2009

the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291;
  • if the results of the ACS and CEA studies, upon further review and analysis, are revised or negated by authorities or by later stage clinical trials;
  • our ability to obtain necessary FDA approvals;
  • our ability to successfully commercialize VIA-2291;
  • our ability to obtain and protect our intellectual property related to our product candidates;
  • our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche;
  • our ability to obtain strategic opportunities to partner and collaborate with large biotechnology or pharmaceutical companies to further develop VIA-2291;
  • our ability to form and maintain collaborative relationships to develop and commercialize our product candidates;
  • general economic and business conditions; and
  • the other risks described under Item IA "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and in our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2008 on file with the SEC.
  • All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.


    '/>"/>
    SOURCE VIA Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
    2. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
    3. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
    4. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
    5. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
    6. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
    7. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
    8. AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
    9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
    10. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
    11. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... July 30, 2015 Sanofi, ... for the second quarter of 2015. CEO ... and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in ... - Performance drivers - ...
    (Date:7/29/2015)... July 29, 2015 US-Australian drug discovery company, ... confirmed it is committed to progressing its ground-breaking technology ... practicable and to ensure the Company delivers the best ... Iain Ross , said the Company currently had ... pre-clinical programs, discovery programs and academic partnerships and initiatives, ...
    (Date:7/29/2015)... 29, 2015  HealthSouth Corporation (NYSE: ... of post-acute healthcare services, offering both facility-based and ... operations for the second quarter ended June 30, 2015. ... by strong volume growth in both segments and ... Jay Grinney, President and Chief Executive Officer of ...
    (Date:7/29/2015)... 29, 2015 Research ... addition of the "Global Biosimilars Market, 2015 ... The Global Biosimilars Market, 2015 - 2025, ... growing biosimilars market. With the blockbuster biologics losing ... costs, biosimilars are being viewed as viable substitutes ...
    Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27
    ... Data into Gems of Knowledge Using discoveryHub™ ... , This paper discusses key problems and opportunities created ... complexity of life science data available today, and presents ... enables rapid ‘harvesting’ and analysis of critical scientific data ...
    ... , ... • Alexa Fluor • TAMRA • ... Flexible and scalable uHTS programs demand that organizations ... the task. This application note describes experiments to assess the performance of ...
    ... Key words: H ... SPA Imaging Beads , , ... important pathophysiological roles in central and peripheral tissues. Generally released from stimulated ... (1).The function of histamine is mediated via four G protein-coupled receptors, H ...
    Cached Biology Technology:Exploiting the Life Science Data Explosion to Speed New Drug Discovery 2Exploiting the Life Science Data Explosion to Speed New Drug Discovery 3Exploiting the Life Science Data Explosion to Speed New Drug Discovery 4Exploiting the Life Science Data Explosion to Speed New Drug Discovery 5Exploiting the Life Science Data Explosion to Speed New Drug Discovery 6Exploiting the Life Science Data Explosion to Speed New Drug Discovery 7Exploiting the Life Science Data Explosion to Speed New Drug Discovery 8Exploiting the Life Science Data Explosion to Speed New Drug Discovery 9Exploiting the Life Science Data Explosion to Speed New Drug Discovery 10Exploiting the Life Science Data Explosion to Speed New Drug Discovery 11Exploiting the Life Science Data Explosion to Speed New Drug Discovery 12Exploiting the Life Science Data Explosion to Speed New Drug Discovery 13Exploiting the Life Science Data Explosion to Speed New Drug Discovery 14Exploiting the Life Science Data Explosion to Speed New Drug Discovery 15Exploiting the Life Science Data Explosion to Speed New Drug Discovery 16Exploiting the Life Science Data Explosion to Speed New Drug Discovery 17Performance of fluorescent dyes with LEADseeker Multimodality Imaging System 2Performance of fluorescent dyes with LEADseeker Multimodality Imaging System 3Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 2Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 3Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 4Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System 5
    (Date:7/9/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/98rrmr/biometrics_for ... "Biometrics for Banking; Market & Technology Analysis, Adoption ... offering. The adoption for banking purposes ... the forecast is that by 2020 it will ... in delivering biometric systems to the banking industry. ...
    (Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
    (Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
    Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
    ... sexes, just so-called mating types. A new study being ... are great similarities between the parts of DNA that determine ... DNA that determine mating types in certain fungi. This ... the evolutionary development of sex chromosomes. In the plant ...
    ... eye diseases and leading causes of blindnessage-related macular degeneration ... drugs that activate a protein found in blood vessel ... Medicine and several other institutions have announced in a ... and even reversed when the protein, Robo4, was activated ...
    ... available in German . In roughly five to ... of breast cancer i.e., hereditary and, thus, genetic factors play a ... are a major cause of familial breast cancer these are ... Germany, 75 percent of familial breast cancers are not attributable to ...
    Cached Biology News:Fungi can tell us about the origin of sex chromosomes 2Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 2Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 3Gene variant increases breast cancer risk 2
    IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
    ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
    The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
    ...
    Biology Products: